Invite a friend to get their first reward.Claim 1000 Satoshis

I'm searching

For Hoomans
NiHowdy > Drug Classes > Substance P/Neurokinin-1 Receptor Antagonists

Browse Medications by Drug Class: Substance P/Neurokinin-1 Receptor Antagonists

Author

Written by Amar Lunagaria

Pharm.D • NiHowdy Founder

Reviewed By

Reviewed by James Wong

Pharm.D • NiHowdy Founder

Published Jan 15, 2025

Fact checked Fact checked

What are Substance P/Neurokinin-1 Receptor Antagonists?

Substance P/Neurokinin-1 (NK-1) receptor antagonists are a class of medications that block the activity of substance P, a neurotransmitter involved in processes such as nausea, vomiting, and pain perception. These drugs are primarily used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. A unique characteristic of NK-1 receptor antagonists is their targeted action on the central nervous system's pathways, effectively controlling symptoms without sedative effects. NiHowdy ensures affordable access to these innovative therapies, helping patients manage challenging conditions with ease.

Stop overpaying for prescriptions

Turn your FREE prescription savings into Bitcoin rewards. It’s that simple!

Sign up for free

Instant savings on prescriptions

Up to 5% back in bitcoind rewards

100% Free – No fees, no subscriptions

List of drugs in Substance P/Neurokinin-1 Receptor Antagonists

Drug NameMore InformationNiHowdy Prices & Bitcoin Rebate

Brief history about Substance P/Neurokinin-1 Receptor Antagonists?

The development of NK-1 receptor antagonists began in the late 20th century with research into substance P and its role in emesis (vomiting). The introduction of aprepitant in the early 2000s revolutionized the prevention of chemotherapy-induced nausea and vomiting (CINV), providing a new standard of care. Since then, newer agents like fosaprepitant and rolapitant have been developed, offering expanded options for patients. These medications have significantly improved the quality of life for individuals undergoing cancer treatment. NiHowdy ensures easy access to these vital medications, supporting patients in overcoming treatment-related challenges.

How do Substance P/Neurokinin-1 Receptor Antagonists work?

NK-1 receptor antagonists work by blocking the neurokinin-1 receptors in the brain and gastrointestinal tract, which are activated by substance P during nausea and vomiting episodes. By inhibiting this pathway, these medications prevent the cascade of signals that trigger emesis. For example, aprepitant is often used in combination with other antiemetic agents, such as serotonin antagonists and corticosteroids, to provide comprehensive control of CINV. NiHowdy ensures patients can access these highly effective treatments affordably, improving their ability to tolerate medical therapies.

What are Substance P/Neurokinin-1 Receptor Antagonists used to treat?

Nausea and Vomiting

NK-1 receptor antagonists are integral to preventing CINV, especially delayed-phase nausea and vomiting, which occur 24-72 hours after chemotherapy. Medications like aprepitant and fosaprepitant are used in combination with other antiemetics to provide complete protection against both acute and delayed symptoms. NK-1 receptor antagonists such as rolapitant are effective in managing PONV, reducing the risk of nausea and vomiting after surgery. They are particularly useful for patients at high risk of these complications, improving recovery and reducing hospital stays. In patients undergoing radiation therapy, NK-1 receptor antagonists help prevent RINV by targeting the neurokinin-1 receptor pathways involved in emesis. This improves patient comfort and adherence to treatment protocols.

Who should consider Substance P/Neurokinin-1 Receptor Antagonists medications?

Adults

Adults undergoing chemotherapy, radiation therapy, or surgery often benefit from NK-1 receptor antagonists to prevent nausea and vomiting. These medications are particularly valuable for individuals with a history of severe nausea or those receiving highly emetogenic therapies.

Children

NK-1 receptor antagonists are used cautiously in pediatric populations, primarily for managing CINV or PONV. Doses are adjusted based on age and weight, and close monitoring ensures safety and efficacy in younger patients.

Seniors

Seniors undergoing medical treatments that induce nausea benefit significantly from NK-1 receptor antagonists. These medications provide targeted relief without causing excessive sedation or cognitive impairment, making them suitable for older adults with complex medical needs.

Are Substance P/Neurokinin-1 Receptor Antagonists safe?

NK-1 receptor antagonists are generally safe when used as prescribed. Common side effects include fatigue, hiccups, and mild gastrointestinal discomfort, which are typically transient and manageable. Rare but serious risks include allergic reactions or interactions with other medications. Regular monitoring and adherence to prescribed regimens ensure the safe use of these medications.

Can I take Substance P/Neurokinin-1 Receptor Antagonists during pregnancy?

The safety of NK-1 receptor antagonists during pregnancy has not been fully established. Pregnant individuals should consult their healthcare provider to evaluate the potential risks and benefits before using these medications.

Are Substance P/Neurokinin-1 Receptor Antagonists safe to take while lactating?

Limited data are available on the use of NK-1 receptor antagonists during breastfeeding. Lactating individuals should consult their healthcare provider to determine the safest options for managing nausea and vomiting.

Are Substance P/Neurokinin-1 Receptor Antagonists controlled substances?

NK-1 receptor antagonists are not classified as controlled substances. They are available by prescription for managing conditions like CINV and PONV. Regular follow-ups with healthcare providers ensure proper use and monitoring.

Side effects of Substance P/Neurokinin-1 Receptor Antagonists?

NK-1 receptor antagonists are well-tolerated but may cause side effects. Common side effects include fatigue, hiccups, dizziness, and mild gastrointestinal discomfort, which are typically temporary and resolve without intervention. Patients are encouraged to maintain hydration and rest to alleviate these symptoms. Less common side effects include headache, constipation, or loss of appetite. These symptoms may require dose adjustments or supportive care to improve tolerability. Rare but serious side effects include severe allergic reactions or drug interactions, especially in patients taking multiple medications. Symptoms like rash, difficulty breathing, or swelling require immediate medical attention. Healthcare providers recommend regular monitoring and adherence to prescribed dosing schedules to minimize side effects and optimize treatment outcomes. Patients should communicate any persistent or severe symptoms promptly for timely intervention.

Join for FREE and start saving now!

Turn your prescription savings into Bitcoin rewards. It’s that simple!

Sign up for free

Instant savings on prescriptions

Up to 5% back in bitcoind rewards

100% Free – No fees, no subscriptions

Cost considerations and insurance coverage for Substance P/Neurokinin-1 Receptor Antagonists

The cost of NK-1 receptor antagonists varies depending on the specific medication and formulation. Generic options, where available, are more affordable, while branded versions may have higher costs. Most insurance plans cover these medications for approved indications like CINV or PONV. NiHowdy offers discounts, rebates, and Bitcoin rewards to make these treatments accessible and cost-effective.

How do I get rebates on Substance P/Neurokinin-1 Receptor Antagonists?

NiHowdy's Bitcoin rebate program for NK-1 receptor antagonists offers patients a unique opportunity to save on healthcare costs while earning potential financial growth. This innovative approach makes managing nausea and vomiting both affordable and rewarding, ensuring access to life-changing treatments while building long-term value.

Medical Conditions treated by Substance P/Neurokinin-1 Receptor Antagonists